 Curis Inc NASDAQ: CRIS presented clinical data from the TakeAim Lymphoma and TakeAim Leukemia studies at the 2022 American Society of Clinical Oncology Annual Meeting. The TakeAim Lymphoma Phase 12 study is investigating emavusertib as monotherapy and in combination with. 